默沙东在AAO 2026公布关键性2B/3期Brunello研究一年期结果,评估Wnt通路三特异性激动剂Remigromig用于糖尿病性黄斑水肿成人患者

美股速递
Oct 11

默沙东在AAO 2026公布关键性2B/3期Brunello研究一年期结果,评估Wnt通路三特异性激动剂Remigromig用于糖尿病性黄斑水肿成人患者

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10